{"data":{"ticker":"CAI","slug":"caris-life-sciences","name":"Caris Life Sciences","exchange":"NASDAQ","sector":"Healthcare","headquarters":"Irving, TX","ceo":"David Dean Halbert M.D.","employees":1846,"website":"https://www.carislifesciences.com","founded":"2008","layers":[{"slug":"ai-healthcare","name":"AI Healthcare"}],"exposure":{"score":78,"tier":"Core","rationale":"Machine learning is central to test interpretation, the Caris Detect early detection launch, and the biopharma data business. The thesis depends on diagnostic reimbursement and clinical adoption, since revenue is billed as testing with sequencing as the substrate."},"quote":{"price":32.1,"change24hPct":-6.5,"change7dPct":-1.09,"change30dPct":13.43,"change1yPct":7.21,"high52w":36.14,"low52w":14.55,"marketCap":9071305728,"peRatio":18.99,"eps":1.69,"volume24h":104427720},"nextEarningsDate":"2026-11-04","summary":"Caris Life Sciences profiles cancer at the molecular level. The company sequences the whole exome and whole transcriptome of patient tumors and applies machine learning to guide diagnosis and therapy selection, earning revenue from tests ordered by oncologists and from biopharma partnerships that use its data platform.","explainer":["Caris Life Sciences profiles cancer at the molecular level. The company sequences the whole exome and whole transcriptome of patient tumors and applies machine learning to guide diagnosis and therapy selection, earning revenue from tests ordered by oncologists and from biopharma partnerships that use its data platform.","Its main products are the MI Profile tissue based molecular profiling service, the Caris Assure blood based assay, and Caris Detect, an AI powered multi cancer early detection blood test launched in 2026. Its models are trained on a clinico genomic database spanning more than a million patient cases.","Founded in 2008 and headquartered in Irving, Texas, Caris employs about 1,800 people and trades on the NASDAQ. It describes itself as an AI TechBio company, positioning its dataset and models as the core asset behind its diagnostics."],"buildoutRole":"Caris operates in the AI Healthcare layer, where sequencing data is the raw material and machine learning is the refinery. Its tests are billed as diagnostics, so revenue rests on sequencing volume, but interpretation, early detection, and its biopharma data business all depend on models trained on its clinico genomic database. The launch of AI driven early detection moves it closer to pure AI monetization, while reimbursement and clinical adoption remain the gating factors.","faq":[{"q":"What does Caris Life Sciences do?","a":"Caris Life Sciences performs molecular profiling of cancer. Oncologists order its tests to sequence a patient's tumor and match findings to therapies, and biopharma companies partner with Caris for target discovery and trial matching using its large clinico genomic database."},{"q":"How is Caris Life Sciences exposed to AI?","a":"Machine learning is central to how Caris interprets sequencing data, powers its Caris Detect early detection test, and monetizes its database. Revenue is billed as diagnostic testing, however. Supercycle rates it Core with an AI Exposure Score of 78 out of 100."},{"q":"What is Caris Detect?","a":"Caris Detect is a blood based multi cancer early detection test launched in 2026. It applies AI trained on billions of molecular markers to whole genome and whole transcriptome sequencing of a blood sample, aiming to find cancers before symptoms appear."},{"q":"Is CAI a pure play AI stock?","a":"No. AI is central to its interpretation and pipeline, but revenue comes from diagnostic testing where sequencing is the substrate. Supercycle places it in the Core tier, reflecting deep AI involvement without pure software economics."},{"q":"Who leads Caris Life Sciences?","a":"Founder David Halbert serves as chairman and chief executive. He founded Caris in 2008 and has kept it focused on building a large clinico genomic database, the asset that now underpins its AI driven diagnostics and biopharma partnerships."}],"history1y":[{"date":"2026-09-22","close":31.47},{"date":"2026-09-23","close":31.65},{"date":"2026-09-24","close":32.27},{"date":"2026-09-25","close":31.98},{"date":"2026-09-28","close":31.75},{"date":"2026-09-29","close":31.55},{"date":"2026-09-30","close":30.63},{"date":"2026-10-01","close":28.35},{"date":"2026-10-02","close":28.3},{"date":"2026-10-05","close":30.39},{"date":"2026-10-06","close":27.45},{"date":"2026-10-07","close":27.1},{"date":"2026-10-08","close":27.5},{"date":"2026-10-09","close":29.7},{"date":"2026-10-12","close":29.69},{"date":"2026-10-13","close":29.53},{"date":"2026-10-14","close":30.25},{"date":"2026-10-15","close":31.76},{"date":"2026-10-16","close":30.56},{"date":"2026-10-19","close":30.71},{"date":"2026-10-20","close":31.11},{"date":"2026-10-21","close":32.35},{"date":"2026-10-22","close":31.71},{"date":"2026-10-23","close":32},{"date":"2026-10-26","close":32.46},{"date":"2026-10-27","close":33.67},{"date":"2026-10-28","close":35.45},{"date":"2026-10-29","close":36.14},{"date":"2026-10-30","close":34.33},{"date":"2026-11-02","close":32.1}],"incomeStatements":[{"ticker":"CAI","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","revenue":812033000,"cost_of_revenue":272865000,"gross_profit":539168000,"operating_expense":0,"operating_income":45113000,"net_income":-68088000,"earnings_per_share":-3.22,"earnings_per_share_diluted":-3.22,"research_and_development":101584000,"selling_general_and_administrative_expenses":392471000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"CAI","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","revenue":412260000,"cost_of_revenue":233478000,"gross_profit":178782000,"operating_expense":0,"operating_income":-257122000,"net_income":-281890000,"earnings_per_share":-1.361,"earnings_per_share_diluted":-1.361,"research_and_development":113916000,"selling_general_and_administrative_expenses":321988000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"CAI","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","revenue":306128000,"cost_of_revenue":216818000,"gross_profit":89310000,"operating_expense":0,"operating_income":-319551000,"net_income":-341415000,"earnings_per_share":-1.8153,"earnings_per_share_diluted":-1.8153,"research_and_development":116883000,"selling_general_and_administrative_expenses":291978000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"CAI","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","revenue":258485000,"cost_of_revenue":178463000,"gross_profit":80022000,"operating_expense":0,"operating_income":-315756000,"net_income":-320827000,"earnings_per_share":-1.5693,"earnings_per_share_diluted":-1.5693,"research_and_development":101268000,"selling_general_and_administrative_expenses":294510000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0}],"balanceSheets":[{"ticker":"CAI","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","total_assets":1125663000,"current_assets":997800000,"cash_and_equivalents":796274000,"total_liabilities":548356000,"current_liabilities":127145000,"total_debt":427686000,"shareholders_equity":577307000,"retained_earnings":-2548736000},{"ticker":"CAI","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","total_assets":343734000,"current_assets":215729000,"cash_and_equivalents":63950000,"total_liabilities":2842572000,"current_liabilities":165423000,"total_debt":424259000,"shareholders_equity":-2498838000,"retained_earnings":-2472300000},{"ticker":"CAI","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","total_assets":412900000,"current_assets":242612000,"cash_and_equivalents":56402000,"total_liabilities":2557850000,"current_liabilities":95138000,"total_debt":217107000,"shareholders_equity":-2144950000,"retained_earnings":-2119175000},{"ticker":"CAI","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","total_assets":717422000,"current_assets":516044000,"cash_and_equivalents":107191000,"total_liabilities":2419535000,"current_liabilities":136906000,"total_debt":270872000,"shareholders_equity":-1702113000,"retained_earnings":-1678650000}],"holders13f":[{"slug":"philippe-laffont","personName":"Philippe Laffont","fundName":"Coatue Management","value":174992258,"portfolioPct":0.003598512507727637,"change":"unchanged","period":"2026-06-30"},{"slug":"stanley-druckenmiller","personName":"Stanley Druckenmiller","fundName":"Duquesne Family Office","value":33759000,"portfolioPct":0.007753168190858524,"change":"unchanged","period":"2026-06-30"}],"news":[]},"meta":{"version":"v1","asOf":"2026-11-02","builtAt":"2026-11-03T05:33:49.985Z","tier":"free","source":"https://supercyclehq.com/stock/caris-life-sciences","disclaimer":"Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.","license":"Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."},"links":{"self":"https://supercyclehq.com/api/v1/stocks/CAI","html":"https://supercyclehq.com/stock/caris-life-sciences","md":"https://supercyclehq.com/stock/caris-life-sciences.md","docs":"https://supercyclehq.com/api/v1/openapi.json"}}